Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1293884 | 0.86 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL14914425 | 0.85 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL12648085 | 0.71 | ALDH1A1 (0.37) | ALDH1A1SMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL2000194 | 0.71 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL18463872 | 0.70 | ALDH1A1 (0.37) | ALDH1A1SMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL1294236 | 0.69 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2MAPTHTTABCG2 | |
| SCHEMBL18463765 | 0.68 | PABPC1 (0.39) | ALDH1A1SMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL17960604 | 0.67 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL27944508 | 0.65 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL13905401 | 0.64 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2HTTRXFP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2499127-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-09-05 | — | — | EP | disclosed |
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| US-9776981-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| US-9303007-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-04-05 | — | — | US | disclosed |
| US-20150322031-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-11-12 | — | — | US | disclosed |
| US-20150322048-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-11-12 | — | — | US | disclosed |
| US-20150197499-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-07-16 | — | — | US | disclosed |
| US-9006455-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-04-14 | — | — | US | disclosed |
| US-20130317213-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2013-11-28 | — | — | US | disclosed |
| US-20130115193-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | HAVCR2, LIPC, PYGL | ALDH1A1 1107/4885SMN1; SMN2 4310/4885NPC1 72/4885 |
| US-20130317213-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, MAVS | ALDH1A1 1627/4885SMN1; SMN2 4690/4885NPC1 357/4885 |
| US-20150322031-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | ALDH1A1 1144/4885SMN1; SMN2 4352/4885NPC1 65/4885 |
| US-20150197499-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | ALDH1A1 1144/4885SMN1; SMN2 4352/4885NPC1 65/4885 |
| US-20150322048-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | ALDH1A1 1144/4885SMN1; SMN2 4352/4885NPC1 65/4885 |
| US-20130115193-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | ALDH1A1 1144/4885SMN1; SMN2 4352/4885NPC1 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.